Biosimilar Characterization Laboratory Opens in Austria
The Christian Doppler Laboratory for Biosimilar Characterization has opened at the Paris-Lodron University of Salzburg (Salzburg, Austria). Co-funded by the Austrian Federal Ministry of Economy, Family, and Youth, as well as the County of Salzburg through the Christian Doppler Society, the laboratory was established to develop and transfer to practice novel and more efficient methods to characterize the active ingredients in protein-based medicines.
The Christian Doppler Laboratory for Biosimilar Characterization has opened at the Paris-Lodron University of Salzburg (Salzburg, Austria). Co-funded by the Austrian Federal Ministry of Economy, Family, and Youth, as well as the County of Salzburg through the Christian Doppler Society, the laboratory was established to develop and transfer to practice novel and more efficient methods to characterize the active ingredients in protein-based medicines. Scientists from the University of Salzburg, Sandoz Pharmaceuticals, and Thermo Fisher Scientific are collaborating in these efforts.
Thermo Fisher Scientific will be providing knowledge in applying liquid chromatography–mass spectrometry (LC–MS) technology and nano-UHPLC (ultrahigh-pressure liquid chromatography) systems and columns.
Professor Christian Huber, head of the Christian Doppler laboratory, commented: “The more physical, chemical, and biological data we can obtain for protein-based drugs, the more certain we can be that they will produce the desired effects and will not produce unexpected adverse effects. Here, we are joining expertise in protein production and characterization, structural biology, and synthetic chemistry at the University of Salzburg to develop innovative characterization tools to determine the efficacy and safety of protein-based medicines.”
Dr Alain Guiller, VP of global sales, life science mass spectrometry at Thermo Fisher Scientific, said: “We are confident that we will make a significant technical contribution to the detailed analysis of biosimilars and their quality control. This is a rapidly-developing field, and this close cooperation with the University of Salzburg and Sandoz will increase our understanding and help us to serve the emerging needs of the pharmaceutical industry.”
Dr Andreas Premstaller, head of Sandoz’ Schaftenau production site, added: “For us, the collaboration constitutes an important means to gain access to very recent technologies for industrial application, in order to make our production safer and more efficient.”
For more information please visit: www.thermofisher.com
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
